Stephen Crosier
Overview
Explore the profile of Stephen Crosier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
735
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Adiamah M, Poole B, Lindsey J, Kohe S, Morcavallo A, Burte F, et al.
Neuro Oncol
. 2024 Oct;
27(1):237-253.
PMID: 39377369
Background: Group 3 medulloblastoma (MBGRP3) represents around 25% of medulloblastomas and is strongly associated with c-MYC (MYC) amplification, which confers significantly worse patient survival. Although elevated MYC expression is a...
2.
Schwalbe E, Lindsey J, Danilenko M, Hill R, Crosier S, Ryan S, et al.
Neuro Oncol
. 2024 Oct;
27(1):222-236.
PMID: 39377358
Background: MYC/MYCN are the most frequent oncogene amplifications in medulloblastoma (MB) and its primary biomarkers of high-risk (HR) disease. However, while many patients' MYC(N)-amplified tumors are treatment-refractory, some achieve long-term...
3.
Kohe S, Bennett C, Burte F, Adiamah M, Rose H, Worthington L, et al.
EBioMedicine
. 2024 Jan;
100:104958.
PMID: 38184938
Background: The malignant childhood brain tumour, medulloblastoma, is classified clinically into molecular groups which guide therapy. DNA-methylation profiling is the current classification 'gold-standard', typically delivered 3-4 weeks post-surgery. Pre-surgery non-invasive...
4.
Burns J, Wilding C, Krasny L, Zhu X, Chadha M, Tam Y, et al.
Nat Commun
. 2023 Jun;
14(1):3834.
PMID: 37386008
Soft tissue sarcomas (STS) are rare and diverse mesenchymal cancers with limited treatment options. Here we undertake comprehensive proteomic profiling of tumour specimens from 321 STS patients representing 11 histological...
5.
Goddard J, Castle J, Southworth E, Fletcher A, Crosier S, Martin-Guerrero I, et al.
Acta Neuropathol
. 2023 Apr;
145(5):651-666.
PMID: 37014508
Group 4 tumours (MB) represent the majority of non-WNT/non-SHH medulloblastomas. Their clinical course is poorly predicted by current risk-factors. MB molecular substructures have been identified (e.g. subgroups/cytogenetics/mutations), however their inter-relationships...
6.
Williamson D, Schwalbe E, Hicks D, Aldinger K, Lindsey J, Crosier S, et al.
Cell Rep
. 2022 Aug;
40(5):111162.
PMID: 35926460
Medulloblastoma is currently subclassified into distinct DNA methylation subgroups/subtypes with particular clinico-molecular features. Using RNA sequencing (RNA-seq) in large, well-annotated cohorts of medulloblastoma, we show that transcriptionally group 3 and...
7.
Danilenko M, Zaka M, Keeling C, Crosier S, Lyman S, Finetti M, et al.
Acta Neuropathol
. 2022 Jul;
144(3):565-578.
PMID: 35831448
We reconstructed the natural history and temporal evolution of the most common childhood brain malignancy, medulloblastoma, by single-cell whole-genome sequencing (sc-WGS) of tumours representing its major molecular sub-classes and clinical...
8.
Richardson S, Hill R, Kui C, Lindsey J, Grabovksa Y, Keeling C, et al.
Neuro Oncol
. 2021 Jul;
24(1):153-165.
PMID: 34272868
Background: Less than 5% of medulloblastoma (MB) patients survive following failure of contemporary radiation-based therapies. Understanding the molecular drivers of medulloblastoma relapse (rMB) will be essential to improve outcomes. Initial...
9.
Crosier S, Hicks D, Schwalbe E, Williamson D, Leigh Nicholson S, Smith A, et al.
Neuropathol Appl Neurobiol
. 2021 Apr;
47(6):736-747.
PMID: 33826763
Aims: Application of advanced molecular pathology in rare tumours is hindered by low sample numbers, access to specialised expertise/technologies and tissue/assay QC and rapid reporting requirements. We assessed the feasibility...
10.
Hill R, Richardson S, Schwalbe E, Hicks D, Lindsey J, Crosier S, et al.
Lancet Child Adolesc Health
. 2020 Nov;
4(12):865-874.
PMID: 33222802
Background: Disease relapse occurs in around 30% of children with medulloblastoma, and is almost universally fatal. We aimed to establish whether the clinical and molecular characteristics of the disease at...